The equivalency of drug products is being questioned with increasing frequency. Oxytetracycline hydrochloride 250-mg capsules produced by the 11 manufacturers supplying the US market were compared in a series of two-way crossover studies with 19 to 22 subjects each. The product (original manufacturer's) associated with the most clinical experience was used as reference product. Serum concentrations of seven comparison products were more variable and markedly lower (P < 0.005) than the reference product two, three, and six hours after ingestion.
Blair DC, Barnes RW, Wildner EL, Murray WJ. Biological Availability of Oxytetracycline HCl Capsules: A Comparison of All Manufacturing Sources Supplying the United States Market. JAMA. 1971;215(2):251–254. doi:10.1001/jama.1971.03180150035007
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: